[강소제약사 리뷰]① 85년 유유제약의 변신…‘반려동물 의약품’ 승부수

Yuyu Pharma's strategic pivot to feline pharmaceuticals targeting FDA approval demonstrates a sophisticated market entry strategy that bypasses crowded domestic regulatory pathways in favor of direct global competition. The company's focus on the underserved cat medication segment within a projected $146 billion pet pharmaceutical market by 2032 exemplifies how specialized therapeutic differentiation can unlock competitive advantage. This approach signals a broader shift among mid-sized Asian pharmaceutical companies toward niche market dominance and regulatory arbitrage as pathways to sustainable global growth.